Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: Results of a case-control study with radiotherapy alone

International Journal of Gynecological Cancer

Volumn 14, Issue 6, 2004, Pages 1112-1117

  Pautier, P ^a   Rey, A ^a   Haie Meder, C ^a   Kerbrat, P ^b   Dutel, J L ^c   Gesta, P ^d   Bryard, F ^a   Morice, P ^a   Duvillard, P ^a   Lhomme C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE EUGÈNE MARQUIS   (France)

^c Centre Hospitalier de Beauvais   (France)

^d Centre Hospitalier de Niort   (France)

Author keywords

Adjuvant; Chemotherapy; Sarcoma; Treatment; Uterine

Indexed keywords

CISPLATIN; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; THROMBOCYTOPENIA; UTERUS SARCOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FRANCE; HUMANS; IFOSFAMIDE; LEIOMYOSARCOMA; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 10044245941     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.14609.x     Document Type: Article

References (27)

1. Pautier P, Genestie C, Rey A et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000;88:1425-31.
2. Omura GA, Blessing JA, Major F et al. A randomized clinical trial of adjuvant adriamycine in uterine sarcomas: a Gynecologic Oncologic Group study. J Clin Oncol 1985;3:1240-5.
3. Pautier P, Genestie C, Fizazi K. Cisplatin-based chemotherapy regimen (DECAY) for uterine sarcomas. Int J Gynecol Cancer 2002;12:749-54.
4. International Federation of Gynecology and Obstetrics. Corpus cancer staging. Int J Gynecol Obstet 1989;28:190.
5. Kaplan ES, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-61.
6. Rose PG, Boutselis JG, Sachs L. Adjuvant therapy for stage I uterine sarcoma. Am J Obstet Gynecol 1987;156:660-2.
7. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647-54.
8. Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, Freedman RS, Wharton JT. High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. Cancer 1987;59:1264-7.
9. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT. A randomized study of adriamycin with and without dimethyl triazinoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626-32.
10. Sutton GP, Blessing JA, Rosenheim N, Photopoulos G, Disaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus. Am J Obstet Gynecol 1989,161:309-12.
11. Sutton G, Blessing J, Barrett R, McGehee R. Phase II trial of ifosfamide and mesna in leimyosarcoma of the uterus: a Gynecologic Oncologic Group study. Am J Obstet Gynecol 1992;166:556-9.
12. Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, Stringer CA, Wharton JT. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 1987;5:618-21.
13. Thigpen JT, Blessing JA, Orr JW Jr, Disaia PJ. Phase II trial of cisplatin in treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncologic Group study. Cancer Treat Rep 1986;70:271-4.
14. Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent uterine sarcomas (a Gynecologic Oncologic Group study). J Clin Oncol 1991;9:1962-6.
15. Bramwell VH, Brugarols A, Mouridsen HT et al. EORTC phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma. Eur J Cancer 1979;15:1511-3.
16. Karakousis CP, Holterman OA, Holyoke ED. Cisdichlorodiamineplatinum (II) in metastatic soft tissue sarcoma. Cancer Treat Rep 1979;63:2027-8.
17. Fizazi K, Cojean I, Le Cesne A et al. Soft tissue sarcomas: general review. Bull Cancer 1994;81:835-52.
18. Piver MS, DeEulis TG, Lele SB, Barlow JJ. Cyclophosphamide, vincristine, adriamycine, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract. Gynecol Oncol 1982;14:319-23.
19. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicine in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 1996;2:226-9.
20. Muss HB, Bundy B, DiSaia PJ et al. Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicine versus doxorubicine and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985;55:1648-53.
21. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-31.
22. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995,13:1600-8.
23. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-an European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-7.
24. Hempling RE, Piver MS, Baker TR. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (Adriamycine), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. Am J Clin Oncol 1995;18:282-6.
25. Buchsbaum HJ, Lifshitz S, Blythe JG. Prophylactic chemotherapy in stages I and II uterine sarcoma. Gynecol Oncol 1979;8:346-8.
26. Hannigan EV, Freedman RS, Rutledge FN. Adjuvant chemotherapy in early uterine sarcoma. Gynecol Oncol 1983;15:56-64.
27. Van Nagell JR, Hanson MB, Donaldson ES, Galion HH. Adjuvant vincristine, dactinomycin, and cyclophosphamide in stage I uterine sarcomas: a pilot study. Cancer 1986;57:1451-4.